Official Title:  A 52-week Randomized, Double -blind, Double -dummy, Active - and 
Placebo -controlled,  Parallel -group, Multicenter Study to Evaluate the 
Efficacy and  Safety of Sotagliflozin compared to Glimepi[INVESTIGATOR_94117] [ADDRESS_104049] Number:  NCT0333277 1 
Document Date: Protocol Version 2: 11-April-20 18